Efficacy and safety of mefenamic acid for the treatment of inflammatory symptoms in patients with COVID-19. (COVID-19) - MEFECOVID-19

Medical School of the University of Colima, Mexico0 个研究点目标入组 40 人开始时间: 2021年8月31日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment

•Outpatients treated at home (without pneumonia and with peripheral blood oxygen saturation equal to or greater than 90% breathing ambient air):
•1. Patients diagnosed with COVID-19, with uncomplicated disease.
•2. Age: 18 years - 85 years old.
•3. Acceptance in writing, with prior information.

•1. Rheumatoid arthritis.
•2. Autoimmune diseases.
•3. Previously diagnosed cardiac diseases (ischemic).
•4. Chronic decompensated systemic disease prior to the diagnosis of COVID-19.
•5. Creatinine 1.25 times higher than the normal value or creatinine clearance less than 50 milliliters / minute (Cockfrot and Gault method), prior to the diagnosis of COVID-19.
•6. Blood hemoglobin less than 10g / Dl, prior to the diagnosis of COVID-19.
•7. Increase in the last month of diastolic blood pressure to 110 mmHg or more and / or appearance of hematuria or proteinuria greater than 300 milligrams / day.
•8. Intestinal pseudo-obstruction. Defined as abdominal pain, with airborne levels on radiographs of the AP abdomen and lateral foot.
•9. Pregnant and lactating women.
•10. Drug addiction (illicit drugs).
•11. Known liver disease prior to the diagnosis of COVID-19 with a doubling of liver function tests (Aspartatoamine transferase (AST), Alaninoamine transferase (ALT), Alkaline phosphatase, Bilirubins).
•12. Presence of Cancer.
•13. Other pathologies at the discretion of the researcher.

发起方

Medical School of the University of Colima, Mexico